Decisions With Patients and Families Regarding Aducanumab in Alzheimer Disease, With Recommendations for Consent
AAN Position Statement
Citation Manager Formats
Make Comment
See Comments

Alzheimer disease (AD) is a feared and stigmatized condition, with relentlessly progressive impact not only on the independence and health of people with dementia, but also on the health and financial well-being of their families, and the overall health care system and society. Further research towards effective treatment for AD is urgently needed, and patients with AD deserve more support from clinicians and from their communities. One essential condition of this support is trust. Whereas it is important to offer hope to patients and families, these efforts will ring hollow if trust is lost. Neurologists and others who serve patients and the broader public health must continually ask: Are the statements and actions of our profession worthy of the trust placed in us by patients and the public?
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Approved by the Ethics, Law, and Humanities Committee, a joint committee of the American Academy of Neurology (AAN), American Neurological Association (ANA), and Child Neurology Society (CNS), on July 23, 2021. Approved by the AAN on August 19, 2021; the ANA on September 22, 2021; and the CNS on November 1, 2021.
Podcast: NPub.org/Podcast9804
- Received August 20, 2021.
- Accepted in final form November 2, 2021.
- © 2021 American Academy of Neurology
Letters: Rapid online correspondence
- Reader Response: Decisions With Patients and Families Regarding Aducanumab in Alzheimer Disease, With Recommendations for Consent: AAN Position Statement
- Robert E. Becker, Psychiatry, clinical pharmacology,, Aristeas Translational Medicine Corporation
Submitted November 23, 2021
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Podcast
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.